To evaluate the efficacy of Paliperidone Palmitate Injection in replacing oral antipsychotics for the treatment of schizophrenia and its impact on social function
Outpatients or inpatients meeting DSM-5 diagnostic criteria forschizophrenia;
Aged 18-65 years (inclusive), regardless of gender;
Currently receiving first- or second-generation oral antipsychotics (excluding clozapine) with stable condition as assessed by the investigator, and PANSS total score ≤80 at screening and baseline;
Signed informed consent by the patient and/or guardian;
Comorbid psychiatric diagnoses other than schizophrenia;
Severe physical diseases, intellectual disability, organic brain disorders, or mental disorders due to physical illnesses;
QTc interval >450 ms (male) or >460 ms (female);
History of psychoactive substance abuse (excluding tobacco) within the past 12 months, or significant suicidal/violent tendencies;